10-Q quarterly report · filed Nov 4, 2026

UroGen Pharma Ltd. (URGN) Q3 2026 10-Q Quarterly Report

Short answer

UroGen Pharma Ltd. (URGN) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $89M (up 223.9% year over year) with net income of −$1M.

Q3 2026 key financials · XBRL

Revenue
$89M
+223.9% YoY · +22.8% QoQ
Net income
−$1M
+95.6% YoY · +89.8% QoQ
Operating margin
9.4%
Gross margin
91.6%
EPS (diluted)
−$0.03
+95.7% YoY · +89.3% QoQ

Source: XBRL data from the UroGen Pharma Ltd. (URGN) Q3 2026 10-Q on SEC EDGAR. USD.

UroGen Pharma Ltd. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $89.0M vs $27.5M, up $61.5M YoY, driven primarily by Zusduri sales
  • Gross margin 91.6% vs 88.1% YoY, operating margin 9.4% vs negative 99.7%
  • Zusduri strongest growth driver, $61.5M revenue increase; Jelmyto standalone revenue not disclosed
  • Cash and marketable securities $90.5M; operating cash use $93.5M through nine months
  • Pharmakon refinancing provided $67.5M financing cash; management expects funding beyond one year, but may need additional capital

Risk Factors

  • New tariff exposure: 15% U.S. tariff on imported mitomycin for Zusduri, effective September 29, 2026
  • New financing structure: $200.0 million Pharmakon tranche refinanced $125.0 million outstanding debt, with $50.0 million available through June 30, 2027
  • Most material operational risk: TAPI currently sole supplier of commercial mitomycin under April 2026 agreement
  • Regulatory risk: FDA staffing reductions and policy changes could delay UGN-103 review, targeting June 14, 2027 action date
  • Near-term market risk: Zusduri commercialization depends on physician adoption as the first FDA-approved nonsurgical treatment for recurrent low-grade intermediate-risk NMIBC

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other UroGen Pharma Ltd. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.